pleas
cite
articl
cornelissen
cg
dreher
hornef
klein
comparison
four
new
commerci
serolog
assay
determin
word
count
abstract
word
count
without
abstract
j
u
r
n
l
p
r
e
p
r
f
highlight
new
igg
assay
identifi
individu
past
infect
combin
two
differ
assay
may
increas
sensit
specif
abstract
background
face
ongo
pandem
caus
sever
acut
respiratori
syndrom
coronaviru
urgent
need
serolog
assay
identifi
individu
past
coronaviru
diseas
result
found
sensit
specif
euroimmun
assay
edi
assay
mikrogen
assay
viram
assay
respect
conclus
commerci
avail
igg
assay
suffici
specif
sensit
identifi
individu
past
infect
decemb
new
coronaviru
caus
coronaviru
diseas
emerg
china
lead
ongo
pandem
revers
transcriptas
realtim
polymeras
chain
reaction
rtpcr
respiratori
specimen
repres
gold
standard
identifi
patient
acut
infect
well
asymptomat
carrier
time
develop
allow
contain
pandem
mani
countri
success
futur
manag
diseas
spread
requir
serolog
detect
past
infect
determin
immun
especi
healthcar
worker
outmost
import
identifi
immun
personnel
treat
vulner
patient
group
plan
manag
infect
prevent
measur
also
allow
identif
plasma
donor
therapeut
intervent
late
sever
commerci
assay
determin
igg
becam
avail
studi
compar
four
assay
respect
sensit
specif
sera
patient
hospit
univers
hospit
rwth
aachen
germani
includ
studi
sera
collect
patient
neg
pcr
result
respiratori
specimen
sera
collect
patient
posit
pcr
result
respiratori
specimen
sampl
data
acquisit
approv
medic
ethic
committe
univers
hospit
rwth
aachen
ek
three
semiquantit
elisa
antisarscovj
u
r
n
l
p
r
e
p
r
f
epitop
diagnost
edi
usa
recomwel
igg
elisa
mikrogen
germani
well
one
qualit
immunoblot
base
set
immunoassay
microarray
format
virachip
igg
immunoblot
viram
germani
compar
studi
detect
igg
antibodi
titer
analog
previou
studi
igg
statu
sera
defin
follow
serum
regard
igg
neg
least
three
four
assay
compar
neg
test
result
appli
manufactur
rate
correct
posit
rate
correct
neg
test
result
four
assay
display
tabl
result
sensit
euroimmun
assay
edi
assay
mikrogen
assay
viram
assay
respect
correspond
result
specif
kinet
igg
antibodi
titer
could
compar
elisa
assay
result
semiquantit
valu
comparison
semiquantit
test
result
normal
describ
studi
design
section
valu
repres
posit
test
result
found
kinet
igg
antibodi
titer
differ
assay
moreov
time
point
seroconvers
assay
differ
patient
one
patient
edi
assay
first
give
posit
test
day
onset
symptom
follow
assay
euroimmun
day
mikrogen
j
u
r
n
l
p
r
e
p
r
f
day
wherea
second
patient
mikrogen
assay
first
give
posit
test
result
day
onset
symptom
follow
assay
edi
day
euroimmun
day
thu
took
least
day
onset
symptom
obtain
posit
test
result
three
assay
also
notic
edi
assay
smaller
rang
linear
compar
test
prevent
proport
detect
increas
antibodi
titer
time
specif
antibodi
usual
detect
one
week
onset
symptom
limit
role
serolog
identif
acut
infect
howev
serolog
assay
urgent
need
supplement
diagnost
repertoir
identifi
patient
past
infect
import
prognosi
cours
pandem
ii
identif
presum
immun
health
care
worker
work
vulner
group
patient
iii
identif
potenti
plasma
donor
therapeut
transfus
furthermor
serolog
assay
might
allow
detect
patient
present
later
stage
diseas
viral
clearanc
may
preced
disappear
symptom
today
elisa
euroimmun
valid
commerci
elisa
avail
germani
accord
recent
public
commerci
igg
specif
elisa
exhibit
lower
specif
sensit
compar
hous
assay
recent
addit
antibodi
test
assay
becam
commerci
avail
aim
studi
compar
four
commerci
avail
serolog
assay
igg
euroimmun
assay
new
igg
assay
strength
edi
assay
high
sensit
howev
found
compar
low
specif
narrow
linear
rang
hand
viram
assay
highli
specif
show
lowest
sensit
euroimmun
assay
mikrogen
assay
medium
sensit
regard
specif
mikrogen
assay
reach
higher
level
euroimmun
assay
test
set
respect
identif
igg
posit
health
care
worker
plasma
donor
high
level
igg
specif
antibodi
specif
linear
rang
import
aspect
assay
thu
euroimmun
assay
mikrogen
assay
appear
suit
fulfil
requir
somewhat
better
perform
mikrogen
assay
experiment
set
conclus
four
test
igg
assay
show
suffici
specif
sensit
identifi
individu
past
infect
moreov
combin
two
differ
assay
may
increas
sensit
specif
especi
earli
time
point
onset
symptom
day
howev
studi
necessari
fulli
assess
perform
assay
fund
research
receiv
specif
grant
fund
agenc
public
commerci
notforprofit
sector
